arrow
S

Steven T. Rosen

Beckman Research Institute of City of Hope
H指数:76
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Humoral and functional SARS-CoV-2-specific T-cell responses elicited in chronic lymphocytic leukaemia patients with GEO-CM04S1 a synthetic MVA-vectored COVID-19 vaccine

体液和功能性的SARS-CoV-2特异性T细胞反应,在慢性淋巴细胞白血病患者中通过GEO-CM04S1这一合成MVA载体COVID-19疫苗所诱导

2025-12-010
OAAI
Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia

靶向METTL1/m7G轴作为髓系白血病的治疗策略

Blood
IF23.1
2025-12-010
PRE
A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

一项Loncastuximab Tesirine联合Mosunetuzumab治疗复发/难治性弥漫大B细胞淋巴瘤的II期研究

BLOOD
IF23.1
2024-11-050
PRE
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
2024-09-012
PRE
8-Cl-Ado and 8-NH2-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia

8-Cl-Ado和8-NH2-Ado与维尼托克协同靶向急性髓系白血病的methionine-MAT2A-SAM轴

LEUKEMIA
IF13.4
2024-04-200
OAAI
Therapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug Discovery
2024-02-232
OAAI
A novel class of inhibitors that disrupts the stability of integrin heterodimers identified by CRISPR-tiling-instructed genetic screens
2024-02-055
OAAI